Thomas Johnson

Evaluating the Uptake, Safety and Effectiveness of the Maternal RSV Vaccine (RSVpreF) Against Infant Bronchiolitis: Preliminary Real-World Evidence

BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of infant hospitalization globally. On September 1, 2024, England introduced the bivalent RSVpreF vaccine for maternal immunization following trial evidence of safety and efficacy. However, real-world data on uptake...